



An Anthem Company

# NEW YORK Provider Communications

## New specialty pharmacy medical step therapy requirements (Herceptin)

Published: Nov 1, 2020 - State & Federal / Medicaid

Effective for dates of service on and after January 1, 2021, the following specialty pharmacy drugs and corresponding codes from current *Clinical Criteria* will be included in our medical step therapy precertification review process. Step therapy review will apply upon precertification initiation or renewal, in addition to the current medical necessity review of all drugs noted below.

The *Clinical Criteria* below will be updated to include the requirement of a preferred agent effective January 1, 2021.

<i>Clinical Criteria</i>	Preferred drug	Nonpreferred drug
ING-CC-0166	Herzuma (Q5113), Kanjinti (Q5117), Ogivri (Q5114), Ontruzant (Q5112), Trazimera (Q5116)	Herceptin (J9355)

*Clinical Criteria* is publicly available on our provider website at [www.empireblue.com/nymedicaiddoc](http://www.empireblue.com/nymedicaiddoc).

### What if I need assistance?

If you have questions about this communication or need assistance with any other item, contact your local Provider Relations representative or call Provider Services toll free at **1-800-450-8753**.

NYE-NU-0257-20 September 2020

**URL:** <https://providernews.empireblue.com/article/new-specialty-pharmacy-medical-step-therapy-requirements-herceptin>

**Featured In:**

November 2020 Empire Provider News

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc. licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans, serving residents and businesses in the 28 eastern and southeastern counties of New York State. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. All external sites will open in a new browser window. Please view our Website Privacy Policy for more information.

---